Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder

BMC Psychiatry

David W Goodman⁶  Brian Scheckner³  Robert Lasser¹  Thomas Babcock³  Bryan Dirks³  Ben Adeyi³  Joel Young²  Richard H Weisler⁴  Greg W Mattingly⁵ 

[1] Formerly of Shire Development LLC, Wayne, PA, USA;Rochester Center for Behavioral Medicine, Rochester Hills, MI, USA;Shire Development LLC, Wayne, PA, USA;Duke University Medical Center, Durham, NC, and University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;St Charles Psychiatric Associates/Midwest Research, 4801 Weldon Spring Pkwy, Suite 300, St. Charles, MO, USA;Johns Hopkins University School of Medicine, Baltimore, MD, USA

关键词: Remission;    Response;    Adults;    Attention-deficit/hyperactivity disorder (ADHD);    Lisdexamfetamine dimesylate (LDX);   

Others  :  1124154
DOI  :  10.1186/1471-244X-13-39

 received in 2011-12-07, accepted in 2013-01-11,  发布年份 2013

【 摘 要 】

Background

Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of 2 studies of lisdexamfetamine dimesylate (LDX) in adults with ADHD.

Methods

In a 4-week, double-blind, forced-dose trial, adults with ADHD were randomized to LDX 30, 50, and 70 mg/day (mg/d) or placebo. In a second, open-label, follow-up trial, adults entering from the 4-week study were titrated to an “optimal” LDX dose (30 mg/d [n=44], 50 mg/d [n=112], and 70 mg/d [n=171]) over 4 weeks, and maintained for 11 additional months. The ADHD Rating Scale IV (ADHD-RS-IV) with adult prompts and the Clinical Global Impressions-Improvement (CGI-I) scale assessed efficacy. Clinical response was defined, post hoc, as ≥30% reduction from baseline in ADHD-RS-IV and CGI-I rating of 1 or 2; symptomatic remission was defined as ADHD-RS-IV total score ≤18. Log rank analysis examined overall significance among the treatment groups in time to response or remission.

Results

Four hundred and fourteen participants in the 4-week study and 345 in the open-label, extension study were included in the efficacy populations. All LDX groups improved by ADHD-RS-IV and CGI-I scores in both studies. In the 4-week study (n=414), 69.3% responded and 45.5% achieved remission with LDX (all doses); 37.1% responded and 16.1% achieved remission with placebo; time (95% CI) to median clinical response (all LDX doses) was 15.0 (15.0, 17.0) days and to remission was 31.0 (28.0, 37.0) days (P<.0001 overall). In the open-label study, with LDX (all doses), 313 (95.7%) and 278 (85.0%) of 327 participants with evaluable maintenance-phase data met criteria for response and remission, respectively. Of participants who completed dose optimization, 75.2% remained responders and 65.7% remained in remission in the 12-month study. Overall, 285 (82.6%) and 227 (65.8%) of 345 participants were responders and remitters, respectively, at their final visits.

Conclusion

In the long-term study, with open-label, dose-optimized LDX treatment, most adults with ADHD achieved clinical response and/or symptomatic remission; almost two-thirds maintained symptomatic remission over the remaining 11 months.

Trial registration

Clinical Trial Numbers: NCT00334880 and NCT01070394

Clinical Trial Registry: clinicaltrials.gov

URLs

http://www.clinicaltrials.gov/show/NCT00334880 webcite

http://www.clinicaltrials.gov/ct2/show/NCT01070394?term=NCT01070394&rank=1 webcite

【 授权许可】

   
2013 Mattingly et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Scahill L, Schwab-Stone M: Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000, 9(3):541-555. vii
• [2]Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, et al.: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723.
• [3]Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 59(9):829-835.
• [4]Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC: Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007, 68(2):268-277.
• [5]Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, on behalf of the 303 study group: Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(9):1364-1373.
• [6]Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, Read SC, Tulloch SJ, on behalf of the SLI381.303 Study group: Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11(8):625-639.
• [7]Culpepper L, Mattingly G: A practical guide to recognition and diagnosis of ADHD in adults in the primary care setting. Postgrad Med 2008, 120(3):16-26.
• [8]Faraone SV, Glatt SJ: A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010, 71(6):754-763.
• [9]DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
• [10]Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991, 48(9):851-855.
• [11]Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, et al.: The international society for bipolar disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009, 11(5):453-473.
• [12]Steele M, Jensen PS, Quinn DMP: Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006, 28(11):1892-1908.
• [13]Guy W: Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218-222.
• [14]Goodman D, Faraone SV, Adler LA, Dirks B, Hamdani M, Weisler R: Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry 2010, 17(3):44-52.
• [15]Biederman J, Mick E, Faraone SV: Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000, 157(5):816-818.
• [16]Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P: 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998, 155(5):646-652.
• [17]American Psychiatric Association: Attention-deficit and disruptive behavior disorders. In Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:85-93.
• [18]Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, et al.: Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001, 40(2):168-179.
• [19]Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose–response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003, 112(5):e404.
• [20]Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L, on behalf of the 304 study group: Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009, 14(10):573-585.
• [21]Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assn 1958, 53:457-481.
• [22]Young J, Mattingly G, Weisler R, Squires L, Adeyi B, Dirks B, Babcock T, Scheckner B: Response and symptomatic remission in a long-term trial of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster Present Am Psychiatr Assoc 162nd Annu Meeting 2009. San Francisco, CA
• [23]Rösler M, Fischer R, Ammer R, Ose C, Retz W: A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009, 259(2):120-129.
• [24]Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, Lee E, Buitelaar JK: A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63(10):981-989.
• [25]Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R: Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009, 12(5):449-459.
• [26]Epstein JN, Langberg JM, Lichtenstein PK, Altaye M, Brinkman WB, House K, Stark LJ: Attention-deficit/hyperactivity disorder outcomes for children treated in community-based pediatric settings. Arch Pediatr Adolesc Med 2010, 164(2):160-165.
• [27]Sciberras E, Roos LE, Efron D: Review of prospective longitudinal studies of children with ADHD: mental health, educational, and social outcomes. Curr Atten Disord Report 2009, 1:1171-1177.
• [28]Buitelaar J, Wilens T, Zhang S, Ning Y, Feldman P: What level of ADHD symptom reduction is necessary for functional improvement? In Abstract presented at: American Psychiatric Association 161st Annual Meeting; May 3–8. Washington, DC: American Psychiatric Association; 2008. Abstract NR6-016
• [29]American Psychiatric Association: DSM-5: The Future of Psychiatric Diagnosis. 2012. http://www.dsm5.org/Pages/Default.aspx webcite. Accessed February 29, 2012